News

Assessing Regeneron Pharmaceuticals: Insights From 26 Financial Analysts
Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.
UBS Raises Regeneron (REGN) Price Target, Maintains Neutral Rating
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst ...
Barchart on MSN4d
Regeneron Pharmaceuticals Earnings Preview: What to Expect
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and ...
Bank of America Securities Reiterated a Sell rating on Regeneron Pharmaceuticals (REGN), Lowered the PT
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...
Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and TG Therapeutics (TGTX)
Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.